司库奇尤单抗治疗恶性肿瘤患者的斑块状银屑病
Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy.
作者信息
Gambardella Alessio
机构信息
Dermatology Unit, University of Campania, Naples, Italy.
出版信息
Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):11-16. doi: 10.1159/000501993. eCollection 2019 Sep-Dec.
Abstract
Although available data are conflicting, psoriasis seems to be associated with an increased baseline risk of malignancy. In addition, some antipsoriatic systemic treatments have been associated with risk of malignancy. There is not enough data on the association of interleukin (IL)-17 and IL-23 inhibitors with malignancy rate, but there have been no cases reported so far. Secukinumab is a recombinant human monoclonal immunoglobulin G1/κ antibody that selectively targets IL-17A; it was demonstrated to be effective and safe for the treatment of moderate to severe psoriasis that may be appropriate in frail subjects, as patients previously experienced malignancy, as in the case reported.
摘要
尽管现有数据存在矛盾，但银屑病似乎与恶性肿瘤的基线风险增加有关。此外，一些银屑病全身治疗与恶性肿瘤风险相关。关于白细胞介素（IL）-17和IL-23抑制剂与恶性肿瘤发生率之间的关联，目前尚无足够数据，但迄今为止尚未有相关病例报告。司库奇尤单抗是一种重组人单克隆免疫球蛋白G1/κ抗体，可选择性靶向IL-17A；已证明其对治疗中度至重度银屑病有效且安全，对于身体虚弱的患者、既往有恶性肿瘤病史的患者（如本报告病例）可能适用。
相似文献
1
Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy.司库奇尤单抗治疗恶性肿瘤患者的斑块状银屑病
Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):11-16. doi: 10.1159/000501993. eCollection 2019 Sep-Dec.
2
Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab.中重度斑块状银屑病治疗中的挑战——司库奇尤单抗的作用
Clin Cosmet Investig Dermatol. 2016 Oct 11;9:347-355. doi: 10.2147/CCID.S81160. eCollection 2016.
3
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.司库奇尤单抗，一种全人源抗白细胞介素-17A 单克隆抗体，在中重度斑块型银屑病患者中显示出最小的免疫原性。
Br J Dermatol. 2017 Mar;176(3):752-758. doi: 10.1111/bjd.14965. Epub 2016 Nov 22.
4
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.司库奇尤单抗：一种用于治疗银屑病的抗白细胞介素-17A生物制剂的综述。
Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16.
5
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review.白细胞介素-17A 抑制剂在慢性斑块状银屑病合并恶性肿瘤病史患者中的应用：一项病例系列研究并系统性文献复习。
Dermatol Ther. 2021 Mar;34(2):e14889. doi: 10.1111/dth.14889. Epub 2021 Feb 25.
6
Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.司库奇尤单抗在印度中重度斑块状银屑病患者中的疗效和安全性：来自FIXTURE的亚组分析，一项随机、安慰剂对照的3期研究
Indian Dermatol Online J. 2017 Jan-Feb;8(1):16-24. doi: 10.4103/2229-5178.198765.
7
Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.司库奇尤单抗治疗中重度斑块状银屑病老年患者的疗效和安全性：III期研究的汇总分析
Drugs Aging. 2018 Feb;35(2):135-144. doi: 10.1007/s40266-018-0520-z.
8
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.司库奇尤单抗，一种全人源抗白细胞介素-17A 单克隆抗体，在接受长达 5 年治疗的银屑病患者中表现出低免疫原性。
J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1733-1741. doi: 10.1111/jdv.15637. Epub 2019 Jun 20.
9
IκBζ is a key player in the antipsoriatic effects of secukinumab.IκBζ 是司库奇尤单抗抗银屑病作用的关键因子。
J Allergy Clin Immunol. 2020 Jan;145(1):379-390. doi: 10.1016/j.jaci.2019.09.029. Epub 2019 Oct 14.
10
Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.司库奇尤单抗——首个用于治疗银屑病的白细胞介素-17A抑制剂。
Indian J Dermatol. 2017 Mar-Apr;62(2):195-199. doi: 10.4103/ijd.IJD_233_16.
引用本文的文献
1
Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab.银屑病管理中生物疗法的最佳使用策略：聚焦司库奇尤单抗
Dermatol Ther (Heidelb). 2025 Sep 4. doi: 10.1007/s13555-025-01515-x.
2
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study.癌症患者银屑病的生物治疗：一项为期8年的回顾性真实世界研究。
J Clin Med. 2024 Mar 27;13(7):1940. doi: 10.3390/jcm13071940.
3
A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders.对诊断为恶性肿瘤后接受生物疗法治疗皮肤病的患者的管理进行回顾性研究。
JAAD Case Rep. 2023 Jul 17;39:81-87. doi: 10.1016/j.jdcr.2023.07.007. eCollection 2023 Sep.
4
TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.肿瘤坏死因子-α抑制剂和乌司奴单抗治疗银屑病：在白细胞介素-17和白细胞介素-23抑制剂时代的治疗效用
J Psoriasis Psoriatic Arthritis. 2022 Apr;7(2):79-92. doi: 10.1177/24755303211047479. Epub 2022 Jan 12.
本文引用的文献
1
Cancer risk in 892 089 patients with psoriasis in Korea: A nationwide population-based cohort study.韩国 892089 例银屑病患者的癌症风险：一项全国基于人群的队列研究。
J Dermatol. 2019 Feb;46(2):95-102. doi: 10.1111/1346-8138.14698. Epub 2018 Nov 16.
2
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.银屑病：哪种疗法适合哪种患者：银屑病合并症和首选的系统药物。
J Am Acad Dermatol. 2019 Jan;80(1):27-40. doi: 10.1016/j.jaad.2018.06.057. Epub 2018 Jul 11.
3
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.司库奇尤单抗治疗中重度斑块状银屑病：一项多中心、回顾性、真实世界研究，观察至 52 周。
Expert Opin Biol Ther. 2018 Jul;18(7):727-735. doi: 10.1080/14712598.2018.1481503. Epub 2018 Jun 6.
4
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).司库奇尤单抗治疗中重度银屑病患者 5 年，疗效持久且安全性良好（SCULPTURE 扩展研究）。
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514. doi: 10.1111/jdv.14878. Epub 2018 Mar 22.
5
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.司库奇尤单抗：一种用于治疗银屑病的抗白细胞介素-17A生物制剂的综述。
Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16.
6
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.银屑病及其治疗的恶性风险与复发：简明更新。
Am J Clin Dermatol. 2018 Jun;19(3):363-375. doi: 10.1007/s40257-017-0337-2.
7
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.司库奇尤单抗对生活质量和银屑病相关症状的影响：CLEAR 52 周研究中与乌司奴单抗的对比分析。
J Am Acad Dermatol. 2018 Apr;78(4):741-748. doi: 10.1016/j.jaad.2017.10.025. Epub 2017 Oct 21.
8
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.通过白细胞介素-17阻断逆转自身免疫毒性和肿瘤反应丧失
N Engl J Med. 2017 May 18;376(20):1989-91. doi: 10.1056/NEJMc1703047.
9
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.司库奇尤单抗在清除中重度斑块型银屑病患者皮肤方面优于乌司奴单抗：来自 CLEAR 研究的结果。
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20.
10
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.靶向肿瘤微环境：与癌症类型相关的白细胞介素-17的促肿瘤作用
Int J Mol Sci. 2016 Aug 30;17(9):1433. doi: 10.3390/ijms17091433.
Zotero 插件